Background: Brain metastasis poses a major treatment challenge and remains an unmet clinical need. Finding novel therapies to prevent and treat brain metastases requires an understanding of the biology and molecular basis of the process, which currently is constrained by a dearth of experimental models and specific therapeutic targets. Methods: Green Fluorescent Protein (GFP)-labeled breast cancer cells were injected via tail vein into SCID/Beige mice (n ¼ 10-15 per group), and metastatic colonization to the brain and lung was evaluated eight weeks later. Knockdown and overexpression of miR-141 were achieved with lentiviral vectors. Serum levels of miR-141 were measured from breast cancer patients (n ¼ 105), and the association with clinical outcome was determined by Kaplan-Meier method. All statistical tests were two-sided. Results: Novel brain metastasis mouse models were developed via tail vein injection of parental triple-negative and human epidermal growth factor receptor 2 (HER2)-overexpressing inflammatory breast cancer lines. Knockdown of miR-141 inhibited metastatic colonization to brain (miR-141 knockdown vs control: SUM149, 0/8 mice vs 6/9 mice, P ¼ .009; MDA-IBC3, 2/14 mice vs 10/15 mice, P ¼ .007). Ectopic expression of miR-141 in nonexpressing MDA-MB-231 enhanced brain metastatic colonization (5/9 mice vs 0/10 mice, P ¼ .02). Furthermore, high miR-141 serum levels were associated with shorter brain metastasis-free survival (P ¼ .04) and were an independent predictor of progression-free survival (hazard ratio [HR] ¼ 4.77, 95% confidence interval [CI] ¼ 2.61 to 8.71, P < .001) and overall survival (HR ¼ 7.22, 95% CI ¼ 3.46 to 15.06, P < .001). Conclusions: Our study suggests miR-141 is a regulator of brain metastasis from breast cancer and should be examined as a biomarker and potential target to prevent and treat brain metastases.
with median survival times ranging from five weeks without treatment to six months with multimodality treatment (4, 5) . Also, the incidence of brain metastases is increasing with the advent of effective targeted systemic therapies for breast cancer such as trastuzumab (3, 6, 7) . Despite the substantial clinical need, the molecular basis for brain metastasis is still poorly understood.
One constraint to understanding the biology of brain metastasis and developing effective treatments is the dearth of preclinical models with which to gain mechanistic insights and identify therapeutic targets. Currently available experimental models have been widely used to elucidate mechanisms by which breast cancer metastasizes to brain (8) (9) (10) (11) (12) (13) and to develop potential therapies (12, (14) (15) (16) . However, most of these models involve technically challenging intracardiac or intracarotidartery injections and have employed only a few human breast cancer cell lines that have been generated by consecutive rounds of in vivo selection. Beyond the limited variability of the models, direct arterial injection of cells bypasses the relevant biology involved in traversing the lungs and surviving in the circulation. Herein, we developed and characterized novel brain metastasis mouse models and investigated the potential role of miR-141 in brain metastatic colonization of breast cancer cells.
Methods

Mouse Studies
Animal protocols were pre-approved by the University of Texas MD Anderson Cancer Center under an Institutional Animal Care and Use Committee (IACUC)-approved protocol (ACUF 07-08-07213). SCID/Beige mice were purchased from Harlan Laboratories (Indianapolis, IN). For tail vein metastasis study, GFP-labeled breast cancer cells were injected into the tail veins of four-to six-week-old female SCID/Beige mice (n ¼ 10-15). For spontaneous metastasis study, cells were transplanted into the cleared mammary fat pads of three-to five-week-old SCID/ Beige mice (n ¼ 8). Details on tumor measurement, resection and imaging are described in the Supplementary Methods (available online).
Patient Samples
The patients (n ¼ 105) who provided serum samples are described elsewhere (17) . The study was approved by the institutional review board at MD Anderson Cancer Center, and informed consent was obtained from each patient. Details on the blood collection and serum miRNA quantification are described in the Supplementary Methods (available online).
Statistical Analysis
The Fisher's exact test was used to compare the rate of metastatic colonization to the brain and lung between treatment groups or between cell lines. The nonparametric Mann Whitney-U test was used to compare the size of brain metastasis in SUM149 and MDA-IBC3 control cells to evaluate miR-141 serum levels in metastatic and nonmetastatic patients. The Kaplan-Meier method was used to evaluate the overall survival (OS) and progression-free survival (PFS) of patients according to serum miR-141 levels, and a log-rank test was used to analyze the differences between groups. Univariate and multivariable Cox proportional hazards regression analyses were performed for PFS and OS. The proportional hazards assumption was tested using the Schoenfeld residuals after fitting the model. All variables with P values of less than .25 from the univariate analysis were included in the multivariable analyses. Data are represented in graphs as means 6 SD. A P value of less than .05 in a two-sided test was considered statistically significant.
Additional methods are available in the Supplementary Methods (available online).
Results
Association of the Epithelial Phenotype and E-cadherin With Brain Metastasis
The cell line SUM149 was derived from invasive ductal carcinoma of a patient with triple-negative (ER-/PR-/HER2-) inflammatory breast cancer (IBC), an aggressive variant of breast cancer characterized by rapid progression and metastasis that has mixed populations of basal and luminal cell types (18, 19) . We injected GFP-labeled SUM149 cells ( Figure 1A ) via tail vein into immunocompromised SCID/Beige mice and using fluorescent stereomicroscopy evaluated the metastatic propensity of these cells to specific organs eight weeks after injection. We found metastatic colonization in the lung and brain ( Figure 1B ) but not in other organs. Cultures of these lung and brain metastases generated sublines that were morphologically distinct ( Figure 1B ): the lung sublines (designated LuMS for lung metastatic sublines) were mesenchymal-like, and the brain sublines (designated BrMS for brain metastatic sublines) were epithelial-like. These sublines were also molecularly distinct: the LuMS demonstrated mesenchymal molecular characteristics, with no expression of the epithelial marker E-cadherin and high expression of mesenchymal markers vimentin, N-cadherin, and Fibronectin; the BrMS expressed markers consistent with an epithelial phenotype ( Figure 1C ). When we cultured the widely used metastasis models MDA-231-BR (brain-seeking) (8) and MDA-231-LM2 (lungseeking) (20) , we observed an epithelial-like morphology and higher expression of the epithelial marker EpCAM/CD326 in the brain-seeking vs lung-seeking MDA-231 sublines, consistent with our findings (Supplementary Figure 1, A Figure 1C , available online). Immunohistochemical staining from our SUM149 xenograft models showed that E-cadherin expression was stronger and more uniform in brain metastases than in lung metastases; conversely, vimentin expression was weaker in the brain metastases ( Figures 1D and 4C ). These observations were supported by publically available gene expression data. Unsupervised clustering revealed segregation of BrMS with the E-cadherin-expressing HMLE cells and LuMS with E-cadherin knockdown HMLE cells ( Figure 1E ) (21) . Hierarchical clustering of the top 50 upregulated and downregulated genes from a recent study in SUM149 cells (22) also revealed that the BrMS clustered with E-cadherin-expressing, Zeb1-low cells (Supplementary Figure 1D , available online). Additionally, the gene expression of the CD49fþ/CD326lo (mesenechymal-like) and CD49fþ/CD326hi (epithelial-like) population of SUM149 parental cells from a study by Perou's group (23) closely resembled expression profiles from LuMS and BrMS, respectively (data not shown). Finally, unbiased transcriptome profiling along with gene set enrichment analysis (GSEA) identified enrichment of E-cadherin stabilization and cell junction ARTICLE organization pathways in BrMS while proteins relevant to the extracellular matrix organization and collagen formation were overrepresented in LuMS ( Figure 1F ), further supporting the potential role of E-cadherin in brain metastasis colonization. Collectively, these findings suggest that E-cadherin expression and the epithelial phenotype can be pro-brain metastasis. We further determined whether the brain and lung metastases variants represent two stable, independent populations vs a single population that readily transitions between epithelial-like and mesenchymal-like states by sorting the parental SUM149 cells into CD49fþ/CD326lo and CD49fþ/CD326hi subpopulations (23) and then culturing cells for five days in vitro. We found that each cell gave rise to the other, suggesting both populations of cells are capable of undergoing EMT-MET cycles (Supplementary Figure 1E , available online).
Given this evidence that developmental programs rather than single regulators may be associated with specific sites of metastases and the broad range of molecular signals ascribed to both MET and EMT, we considered that broad regulation by individual microRNAs might be a programmatic regulator of brain metastases. To identify microRNAs that could mediate lung-or brain-specific metastasis, we performed microRNA microarray analysis of the LuMS and BrMS sublines. Unsupervised hierarchical cluster analysis showed that LuMS clustered distinctly from that of BrMS and that the miR-200s, including miR-141, miR-200a, miR-200b, and miR-200c, were overexpressed in BrMS (P < .001, FDR ¼ 0.05) ( Figure 1G ). The parental SUM149 cell line clustered with BrMS but shared differentially expressed microRNAs with both BrMS and LuMS (P ¼ .001, FDR ¼ 0.1) (Supplementary Figure 1F , available online). The miR-200s were previously shown to regulate E-cadherin and enforce the epithelial phenotype (24, 25) . Thus, these expression data agree with our earlier observations suggesting the epithelial phenotype can be pro-brain metastasis. We used the following breast cancer cell lines to validate the microRNA microarray data: 
Generation of Novel Brain Metastasis Xenograft Mouse Models
We assessed the metastatic colonization after tail vein injection of parental GFP-labeled SUM149 and MDA-IBC3 cell lines into immunocompromised SCID/Beige mice. The percentage of brain metastasis eight weeks after injection was 66.7% (6/9 mice) ( Figure 2A 
Impact of miR-141 Knockdown on Brain Metastatic Colonization in Preclinical Mouse Models
To investigate the role of miR-200s in brain metastasis, we selected two of the miR-200s (miR-141 and miR-200a) that were most strongly expressed in our miRNA microarray ( Figure 1G ). Figure 2 , B-E. Overt brain metastasis lesions generated in mouse xenografts recapitulated the receptor status of each cell line, triple-receptor-negative SUM149 and HER2-overexpressing MDA-IBC3 ( Figure 3A ). Also, a high level of miR-141expression was demonstrated by in situ hybridization in the metastatic brain lesions from SUM149-and MDA-IBC3-injected mice ( Figure 3B ). Immunostaining of histologic sections from the lung and brain metastases showed highly proliferative Ki-67-positive cells in both SUM149 and MDA-IBC3 xenografts; SUM149 metastases were strongly cytokeratin (CK) 5/6-positive while MDA-IBC3 were CK5/6-negative ( Figure 4, A and B ). E-cadherin was expressed statistically significantly more highly in tissue sections from brain metastases compared with lung metastasis sections in both cell lines (P < .03) ( Figure 4C ). To confirm that the observed pro-brain metastasis role in xenografts is unique to miR-141, we conducted studies after knockdown of an invariant (not differentially expressed) microRNA, miR-19a, in SUM149 cells (Supplementary Figure 7A , available online). miR-19a KD resulted in upregulation of miR-19a known target genes Tsp1 and SOCS1 (Supplementary Figure 7 , B and C, available online). The incidence of brain metastasis was not statistically different between miR-19a KD and control SUM149 cells (control: 5/8 mice; miR-19a KD: 3/10 mice, P ¼ .34). Similarly, the incidence of lung metastasis in the two groups was not different (control: 7/8 mice; miR-19a KD: 7/10 mice, P ¼ .59).
To evaluate if miR-141 plays a similar pro-brain metastasis role in an orthotopic model, we developed a spontaneous brain metastasis model from breast cancer using the MDA-IBC-3 cell line after orthotopic transplantation into the cleared mammary fat pad followed by resection of primary tumor to allow the colonization of cells to distant organs. Two months after resection, four of seven mice developed brain metastasis from parental MDA-IBC3 while none of the mice injected with miR-141 KD MDA-IBC3 cells developed brain metastasis (P ¼ .03) ( Figure 5,  A and B) . Staining of the brain metastasis tissues showed a strong and uniform E-cadherin expression, similar to the tail vein mouse models ( Figure 5C ).
Ectopic Expression of miR-141 in Low-Expressing Breast Cancer Cells and its Effect on Brain Metastasis
We next sought to determine if the increased brain metastasis observed with these two parental, miR-141-expressing IBC cell lines specifically reflects the propensity of IBC cells to colonize the brain or whether miR-141 expression is sufficient to drive brain metastases in non-IBC cell lines that express low endogenous miR-141. To address this question, we selected MDA-231, a non-IBC, claudin-low breast cancer cell line that has low endogenous miR-141 expression and has not been shown previously to metastasize to the brain after tail vein injection (20, 26) . This cell line was transduced with GFP-labeled, miR-141-overexpressing (miR-141 OE) or control lentiviral vectors. Overexpression of miR-141 in MDA-231 cells was confirmed by real-time polymerase 
Prognostic Relevance of Serum miR-141 Levels in Breast Cancer Patients
We measured miR-141 levels in serum samples from patients with breast cancer (n ¼ 105) (17) and evaluated associations with clinicopathologic factors and clinical outcomes. We found that patients with metastatic IBC had higher serum miR-141 levels than patients with locally advanced breast cancer or patients with metastatic non-IBC (P ¼ .01) ( Figure 8A ). Univariate analysis showed that serum miR-141 levels (P < .001), stage (P < .001), triple-negative receptor status (P < .001) and treatment status (P < .001) were statistically significantly associated with progression-free survival (PFS) and overall survival (OS) while age, grade, and IBC status were not associated with PFS or OS (P < .05) (data not shown). High serum miR-141 levels were associated with shorter PFS (4.2 vs 7.8 months, P ¼ .002) and shorter OS (12.3 vs 27.8 months, P ¼ .001) in patients with metastatic breast cancer as shown in the representative Kaplan-Meier curves ( Figure 8 , B and C). On multivariable analysis, miR-141 was an independent predictor of progression-free (hazard ratio Notably, a high miR-141 serum level was associated with shorter brain metastasis-free survival (P ¼ .04) ( Figure 8D ).
Discussion
We demonstrated that E-cadherin and epithelial expression patterns are associated with brain metastases in our xenograft mouse models and that miR-141, a known inducer of the epithelial phenotype and a key regulator of E-cadherin, is necessary for metastatic colonization of breast cancer cells to the brain. We characterized brain metastases from heterogeneous cell lines that have not previously been associated with brain metastases, and we provided clinical evidence supporting the prognostic relevance of miR-141. EMT is widely thought to be central to cancer metastasis (27, 28) , and miR-200s have been shown to inhibit EMT and promote MET (24, 25) , suggesting that miR-200s likely suppress metastasis. However, functional studies in different models of metastasis have generated contradictory results, with some studies showing that miR-200s promote metastasis and others that miR-200s suppress metastasis (29) (30) (31) . This discrepancy may be attributed to the role miR-200 plays as a potential regulator of reversible EMT-MET transition, as demonstrated by Korpal et al. (32) . None of these functional studies examined the role of miR-200s on metastatic colonization specifically to the brain. Our findings demonstrated that metastasis to the brain can occur as a function of MET, rather than EMT, with expression of several 'epithelial' microRNAs, including miR-200s and E-cadherin, elevated in brain metastatic samples. In addition, knockdown of miR-141, one of the 'epithelial' microRNAs, blocked metastasis to the brain. In contrast, metastases in the lung showed EMT features and miR-141 knockdown did not prevent metastasis to the lung. Our findings suggest that EMT may be central to cancer metastasis to organs such as the lung but Further investigation is warranted on the interactions between breast cancer cells and the lung and its microenvironment in order to understand the metastatic escape or reseeding process. Furthermore, it is not clear how epithelial differentiation promotes brain metastases. Zhang and colleagues recently demonstrated that the osteogenic niche boosts tumor cell proliferation through heterotypic adherens junctions between breast cancer cell E-cadherin and osteogenic N-cadherin (33) . The role of heterotypic cadherin junctions in brain metastasis initiation and colonization needs to be explored.
Our study is not without limitations. First, we note that our study with miR-141 serum samples from metastatic breast cancer patients was limited because of the low number of cases with brain metastasis and the variable time of blood draw during treatment course in the samples available for this study. Second, miR-141 promoted brain metastasis in aggressive cell lines with some epithelial phenotype but not in a metaplastic cell line that is less plastic and has greater commitment to the mesenchymal phenotype, limiting generalizability of our findings.
In conclusion, we describe herein a key regulator of brain metastasis and have increased preclinical mouse models for studying brain metastasis. This study may provide insights into the regulation of brain metastasis from breast cancer and has a potential to lead to the development of therapies for brain metastases in addition to fundamentally advancing the field of brain metastasis research. Further studies to explore the utility of miR-141 as a biomarker for brain metastases and a potential target for the prevention and treatment of brain metastases are warranted. 
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